Publications dans lesquelles il/elle collabore avec Jesús María Prieto Valtueña (44)

2016

  1. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Usage of Adenovirus Expressing Thymidine Kinase Mediated Hepatocellular Damage for Enabling Mouse Liver Repopulation with Allogenic or Xenogenic Hepatocytes

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

2011

  1. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma

    Functional and Integrative Genomics, Vol. 11, Núm. 3, pp. 419-429

  2. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

    Cancer Research, Vol. 71, Núm. 9, pp. 3214-3224

  3. Cardiotrophin-1 promotes a high survival rate in rabbits with lethal fulminant hepatitis of viral origin

    Journal of Virology, Vol. 85, Núm. 24, pp. 13124-13132

  4. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells

    Hepatology, Vol. 54, Núm. 1, pp. 28-37

  5. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  6. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

  2. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells

    European Journal of Immunology, Vol. 40, Núm. 12, pp. 3389-3402

  3. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

    Vaccine, Vol. 28, Núm. 44, pp. 7146-7154

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

2008

  1. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1

    Journal of Immunology, Vol. 181, Núm. 1, pp. 126-135